The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy
Status:
Active, not recruiting
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
Many families of children with medically refractory epilepsy are choosing to use medicinal
cannabinoids (MCBD) as an adjunctive alternative treatment option. The safety, tolerability
and efficacy of these products are not known. The primary objective of this study is to
determine how the use of MCBD affects children with medically refractory epilepsy in an
observational study. Measures of evaluation to be used will include: laboratory values,
developmental measures, seizure diaries and serial electroencephalographic (EEG) recordings.
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
Colorado Department of Public Health and Environment